Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Pharmaceutical Biotechnology|January 19, 2016
Therapeutic Boosting of the Immune Response: Turning to CD14 for HelpAnne-Catherine Raby, Mario O Labéta
Intensive Care Medicine Experimental|January 17, 2017
Soluble Toll-like receptor 2 is a biomarker for sepsis in critically ill patients with multi-organ failure within 12 h of ICU admissionBenjamin Holst, Tamas Szakmany, Anne-Catherine Raby, et al.
Kidney International|June 5, 2018
Targeting Toll-like receptors with soluble Toll-like receptor 2 prevents peritoneal dialysis solution-induced fibrosisAnne-Catherine Raby, Guadalupe T González-Mateo, Aled Williams, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2006
Modulation of neonatal microbial recognition: TLR-mediated innate immune responses are specifically and differentially modulated by human milkEmmanuel LeBouder, Julia E Rey-Nores, Anne-Catherine Raby, et al.
Journal of the American Society of Nephrology : JASN|July 20, 2016
Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated FibrosisAnne-Catherine Raby, Chantal S Colmont, Ann Kift-Morgan, et al.
Frontiers in Cellular and Infection Microbiology|December 14, 2023
Calprotectin blockade inhibits long-term vascular pathology following peritoneal dialysis-associated bacterial infectionEsra Cetin, Morgane Mazzarino, Guadalupe T González-Mateo, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 3, 2011
Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptorsChantal S Colmont, Anne-Catherine Raby, Vincent Dioszeghy, et al.
Frontiers in Immunology|October 18, 2023
Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathologyMorgane Mazzarino, Esra Cetin, Maria Bartosova, et al.
Pageof 2